Log In Get Started
Stock Markets July 14, 2026 02:23 PM

Medical device shares slide after HCA flags weaker surgical activity

Preliminary second-quarter data from HCA Healthcare points to softer-than-expected procedure volumes, sparking a broad pullback across medtech names

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
HCA GEHC ISRG SYK GMED

Shares of prominent medical device makers fell sharply following preliminary second-quarter results from HCA Healthcare that showed weaker surgical volumes than anticipated. The rout saw double-digit pressure across several large-cap device stocks, as analysts warned the weaker hospital surgical activity may depress demand for devices tied to elective procedures, particularly among patients under 65.

Medical device shares slide after HCA flags weaker surgical activity
HCA GEHC ISRG SYK GMED
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • HCA Healthcare's preliminary second-quarter results showed weaker-than-expected surgical volumes, prompting market concerns about device demand.
  • Several major medical device makers saw share price declines: GEHC -7%, ISRG -6%, SYK -5.4%, GMED -5.25%, MDT -4.7%, BSX/BAX/TNDM -4% each, ZBH -3%, INSP -3.75%.
  • Analysts expect the HCA update to be discussed on second-quarter earnings calls, with particular focus on elective procedures among patients under 65 versus non-elective procedures in older patients.

Major medical device manufacturers experienced notable share price drops on Tuesday after HCA Healthcare (NYSE:HCA) released preliminary second-quarter figures indicating softer surgical procedure volumes than expected. The market reaction was broad, with multiple device and equipment makers seeing declines.

GE Healthcare (NASDAQ:GEHC) led the losses among the larger names, falling 7%. Intuitive Surgical (NASDAQ:ISRG) declined 6%. Other declines included Stryker (NYSE:SYK) down 5.4%, Globus Medical (NYSE:GMED) off 5.25%, and Medtronic (NYSE:MDT) down 4.7%. Boston Scientific (NYSE:BSX), Baxter International (NYSE:BAX) and Tandem Diabetes (NASDAQ:TNDM) each fell 4%. Zimmer Biomet (NYSE:ZBH) slid 3% while Inspire Medical (NYSE:INSP) declined 3.75%.

HCA Healthcare's preliminary results explicitly pointed to softer surgical volumes over the quarter, a development that prompted investors to reassess demand prospects for devices and hospital equipment. The weaker activity at hospitals raises questions about near-term procedure-driven revenue for medtech companies.

Wells Fargo analyst Larry Biegelsen said he expects medical technology shares to react negatively to HCA's preliminary data and predicted the topic would be a focal point during second-quarter earnings calls across the sector. Biegelsen highlighted a divergence in the types of procedures affected: elective operations appear to be down primarily among patients under 65 - categories that include orthopedic and spine interventions - while non-elective procedures common in patients over 65, such as many cardiovascular operations, are less affected by the observed weakness.

The market-wide pullback in device stocks reflects investor concern that reduced surgical volumes at hospitals could translate into lower demand for related products and equipment in upcoming quarters. These shifts in hospital procedure mix and volumes are being watched closely by analysts and market participants as they consider revenue exposures for medtech companies.

Sectors impacted:

  • Medical devices and equipment
  • Hospital services and operators
  • Health-care suppliers tied to elective procedures

Risks

  • Continued softness in hospital surgical volumes could reduce near-term demand for medical devices and equipment, affecting medtech revenue - impacts are concentrated in the medical devices and hospital supplier sectors.
  • Elective procedures, especially orthopedic and spine operations concentrated in patients under 65, appear most exposed; a sustained decline could weigh on companies with high exposure to these procedure types.
  • If hospitals' procedure mix remains skewed away from device-intensive elective surgeries, device manufacturers may face increased revenue uncertainty in upcoming quarters.

More from Stock Markets

Celcuity Shares Rally as FDA Decision on Gedatolisib Looms Jul 14, 2026 Interactive Brokers options data point to 4.6% expected move for July 21 earnings Jul 14, 2026 Options Signal 4.3% Move for Capital One Ahead of July 21 Results Jul 14, 2026 Public health groups sue FDA over policy allowing some unauthorized vaping products to remain on market Jul 14, 2026 Options Point to 4.2% Move for MSCI Ahead of July 21 Results Jul 14, 2026